P210034/S001: Agili-C
FDA’s recorded scope: Approval for updated package labeling that incorporates the clinical results from the required postapproval study.
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 1 FDA record to the applicant name Smith and Nephew, Inc.. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jun 4, 2026 to Jun 4, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code QRU appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P210034, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 150 Minuteman Rd., Andover, MA, 01810. Recorded on P210034/S001, decision dated Jun 4, 2026.
Implant, resorbable, for articular osteochondral repair.
FDA’s recorded scope: Approval for updated package labeling that incorporates the clinical results from the required postapproval study.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Agili-CP210034/S001 | Smith and Nephew, Inc. | PMA supplement | Jun 4, 2026 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.